PHARMAEXPO LTD - Filleted accounts

Registered number

12993595

PHARMAEXPO LTD

Unaudited Filleted Accounts

31 December 2024

PHARMAEXPO LTD
Registered number:		12993595
Balance Sheet
as at 31 December 2024

Notes			2024			2023
£				£
Current assets
Stocks		60,000			-
Debtors	4	100,000			156,940
Cash at bank and in hand		67,078			144,369
		227,078			301,309

Creditors: amounts falling due within one year	5	(192,333)			(122,942)

Net current assets			34,745			178,367

Net assets			34,745			178,367

Capital and reserves
Called up share capital			4			4
Profit and loss account			34,741			178,363

Shareholders' funds			34,745			178,367

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.




Yousef Yaghoubi
Director
Approved by the board on 24 December 2025

PHARMAEXPO LTD
Notes to the Accounts
for the year ended 31 December 2024


1	Accounting policies

	Basis of preparation
	The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

	Turnover
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

	Tangible fixed assets
	Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

	Plant and machinery	Straight line at 50%
	Office equipment	Straight line at 33%

	Cash and cash equivalents
	Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

	Stocks
	Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.

	Debtors
	Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.







	Creditors
	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

	Taxation
	The tax expense for the period comprises tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

	Provisions
	Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

	Borrowings
	Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing. Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

	Share Capital
	Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

	Dividends
	Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.


2	Employees			2024		2023
Number					Number

	Average number of persons employed by the company			6		1







3	Tangible fixed assets
		Plant and machinery etc		Office Equipment		Total
£			£		£
	Cost
	At 1 January 2024	70,000		9,538		79,538
	At 31 December 2024	70,000		9,538		79,538

	Depreciation
	At 1 January 2024	70,000		9,538		79,538
	At 31 December 2024	70,000		9,538		79,538

	Net book value
	At 31 December 2024	-		-		-


4	Debtors			2024		2023
£					£

	Other debtors			100,000		156,940


5	Creditors: amounts falling due within one year			2024		2023
£					£

	Bank loans and overdrafts			9,011		9,337
	Trade creditors			950		110
	Taxation and social security costs			(751,304)		2,493
	Other creditors			933,676		111,002
				192,333		122,942


6	Other information

	PHARMAEXPO LTD is a private company limited by shares and incorporated in England. Its registered office is:
	277-279 Chiswick High Road
	London
	W4 4PU